

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

### **石藥集團有限公司**

*(Incorporated in Hong Kong under the Companies Ordinance)*

**(Stock code: 1093)**

### **APPOINTMENT OF VICE-CHAIRMAN AND ROTATING CHIEF EXECUTIVE OFFICER**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”) together with its subsidiaries, collectively the “**Group**”) hereby announces that Mr. Pan Waidong (“**Mr. PAN**”), an executive director of the Company, has been appointed as the vice-Chairman and Rotating Chief Executive Officer of the Company with effect from 25 May 2017.

The biographical details of Mr. PAN are set out below:

Mr. PAN, aged 47, was appointed as an executive director in 2006. He is also a director of certain subsidiaries of the Group. Mr. PAN holds an EMBA degree from Tsinghua University and has extensive finance, accounting, investment and management experience in the pharmaceutical industry. Mr. PAN is also director of Massive Giant Group Limited, Massive Top Limited and March Rise Limited, all of which are substantial shareholders of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “SFO”). Mr. PAN has entered into a service contract as an executive Director for a term of 3 years commencing from 1 April 2015. He is also subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the articles of association of the Company. His director’s fee is to be determined by the Board and to be authorised by the shareholders of the Company at the annual general meeting with reference to his performance and responsibilities, performance of the Group and prevailing market practices. Mr. PAN received a director’s fee of HK\$60,000 and other remuneration of HK\$2,603,000 for the year ended 31 December 2016. Mr. PAN does not receive any remuneration for acting as the vice-Chairman and Rotating Chief Executive Officer.

Save as disclosed above, Mr. PAN (i) has not held any other positions with any members of the Group; (ii) is not related to any director, senior management, substantial shareholders of the Company or controlling shareholders of the Company or other members of the Group; (iii) is not interested in the shares of the Company within the meaning of Part XV of the SFO; and (iv) has not held any other directorships in any other listed public companies in the last three years. Save as disclosed above, Mr. PAN has confirmed that there are no other matters that need to be brought to the attention of the shareholders of the Company in connection with the aforesaid appointment and there are no information that should be disclosed pursuant to rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board would like to take this opportunity to welcome Mr. PAN to the new positions.

By order of the board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 25 May 2017

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. PAN Weidong, Mr. WANG Huaiyu, Mr. LU Jianmin, Mr. WANG Jinxu, Mr. WANG Zhenguo, Mr. LU Hua and Mr. CHAK Kin Man as executive Directors; Mr. LEE Ka Sze, Carmelo as non-executive Director and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Chuan as independent non-executive Directors.*